Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 1:23 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 769–792 of 4,637 matching trials from the live ClinicalTrials.gov search.

Filters: Los Angeles, California Clear all

Conditions: Osteoarthritis
Interventions: glucosamine, chondroitin sulfate, glucosamine and chondroitin sulfate combined, celecoxib; Drug
Lead sponsor: US Department of Veterans Affairs; Federal
Eligibility: 40 Years and older
Enrollment: 1,588 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2004
U.S. locations: 16
States / cities: Birmingham, Alabama • Tucson, Arizona • Los Angeles, California + 12 more

Conditions: Solid Tumor
Interventions: 68Ga-FAP-2286, 177Lu-FAP-2286; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 222 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 20
States / cities: Birmingham, Alabama • Duarte, California • Irvine, California + 16 more

Conditions: Autism
Interventions: Caregiver joint attention intervention; Behavioral
Lead sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); NIH
Eligibility: 12 Months to 36 Months
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2006
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Cystic Fibrosis, Nontuberculous Mycobacterial Lung Disease, Nontuberculous Mycobacterium Infection, Mycobacterium Infections, Mycobacterium; Pulmonary
Interventions: mycobacteriophage; Biological
Lead sponsor: National Jewish Health; Other
Eligibility: 6 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 18
States / cities: Birmingham, Alabama • Los Angeles, California • San Diego, California + 14 more

Conditions: Pneumonia, Pneumocystis Carinii, HIV Infections
Interventions: Trimetrexate glucuronate, Pentamidine isethionate, Sulfamethoxazole-Trimethoprim, Leucovorin calcium; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 12 Years and older
Enrollment: 364 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1991
U.S. locations: 23
States / cities: Los Angeles, California • Washington D.C., District of Columbia • Miami, Florida + 15 more

Conditions: Cancer Harboring BRAF Alterations, HGG, LGG, Solid Tumors
Interventions: Plixorafenib; Drug
Lead sponsor: Fore Biotherapeutics; Industry
Eligibility: 8 Years and older
Enrollment: 254 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 30
States / cities: Beverly Hills, California • San Francisco, California • Westwood, Los Angeles, California + 23 more

Conditions: Pediatric Hydrocephalus
Interventions: Not listed
Lead sponsor: University of Utah; Other
Eligibility: Up to 18 Years
Enrollment: 1,400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2029
U.S. locations: 11
States / cities: Birmingham, Alabama • Los Angeles, California • Aurora, Colorado + 8 more

Conditions: HIV Infection, Menopause
Interventions: Transdermal estradiol gel, Micronized Progesterone, Placebo for estradiol gel, Placebo for micronized progesterone; Drug
Lead sponsor: Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections; Network
Eligibility: 40 Years to 60 Years · Female only
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 23
States / cities: Birmingham, Alabama • Los Angeles, California • San Diego, California + 18 more

Conditions: Gliosarcoma, MGMT-Unmethylated Glioblastoma
Interventions: Contrast-enhanced Magnetic Resonance Imaging, Ipilimumab, Nivolumab, NovoTTF-100A Device, Quality-of-Life Assessment, Questionnaire Administration, Radiation Therapy, Temozolomide; Procedure · Biological · Device + 3 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 159 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 285
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Anaheim, California + 210 more

Conditions: Arteriovenous Graft
Interventions: SRM003, Participating Site's standard practice; Biological · Other
Lead sponsor: Shire; Industry
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 46
States / cities: Phoenix, Arizona • Tucson, Arizona • Fresno, California + 40 more

Conditions: Pemphigus Vulgaris
Interventions: Mycophenolate Mofetil Placebo, Mycophenolate Mofetil, Rituximab, Rituximab Placebo; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 135 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 15
States / cities: Birmingham, Alabama • Tucson, Arizona • Sacramento, California + 12 more

Conditions: Preoperative Aerobic Training, Solid Tumors
Interventions: treadmill walking (Proof-of-Concept), treadmill walking Dose-Finding / Escalation; Behavioral
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 19 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 8
States / cities: Los Angeles, California • Basking Ridge, New Jersey • Middletown, New Jersey + 5 more

Conditions: Melanoma
Interventions: Ipilimumab; Biological
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 831 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 11
States / cities: Los Angeles, California • Jacksonville, Florida • Orlando, Florida + 7 more

Conditions: Multiple Sclerosis (MS)
Interventions: Fingolimod, Ofatumumab, Siponimod, Fingolimod placebo, Siponimod placebo, Ofatumumab placebo; Drug · Other
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 10 Years to 17 Years
Enrollment: 129 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2031
U.S. locations: 6
States / cities: Little Rock, Arkansas • Los Angeles, California • Washington D.C., District of Columbia + 3 more

Conditions: Quality Improvement
Interventions: GenAI Chart Summarization; Other
Lead sponsor: University of California, Los Angeles; Other
Eligibility: Not listed
Enrollment: 284 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Surgery, Anesthesia
Interventions: Pulse CO-Oximeter sensor; Device
Lead sponsor: Masimo Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Liver Injury
Interventions: Omegaven™, Historical Controls; Drug · Other
Lead sponsor: Children's Hospital Los Angeles; Other
Eligibility: Up to 21 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2019
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: HIV Infections, Pregnancy
Interventions: Nevirapine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years to 60 Years · Female only
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1998
U.S. locations: 15
States / cities: La Jolla, California • Los Angeles, California • San Francisco, California + 7 more

Conditions: Glioma, Anaplastic Astrocytoma, Anaplastic Astro-oligodendroglioma, Glioblastoma
Interventions: autologous tumor lysate-pulsed DC vaccination, Tumor lysate-pulsed DC vaccination+0.2% resiquimod, Tumor-lysate pulsed DC vaccination +adjuvant polyICLC; Biological
Lead sponsor: Jonsson Comprehensive Cancer Center; Other
Eligibility: 18 Years to 70 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2024
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Solid Tumor
Interventions: Topotecan, Sorafenib; Drug
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 3 Years to 18 Years
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 9
States / cities: Los Angeles, California • Hartford, Connecticut • Wilmington, Delaware + 6 more

Conditions: Pancreatic Adenocarcinoma, Pancreatic Ductal Adenocarcinoma, Pancreatic Intraductal Papillary-Mucinous Neoplasm, Stage I Pancreatic Cancer AJCC v6 and v7, Stage II Pancreatic Cancer AJCC v6 and v7
Interventions: 3-Dimensional Conformal Radiation Therapy, Biospecimen Collection, Capecitabine, Chemotherapy, Computed Tomography, Erlotinib Hydrochloride, Fluorouracil, Gemcitabine Hydrochloride, Intensity-Modulated Radiation Therapy, Magnetic Resonance Imaging, Quality-of-Life Assessment, X-Ray Imaging; Radiation · Procedure · Drug + 1 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 546 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2025
U.S. locations: 678
States / cities: Mobile, Alabama • Anchorage, Alaska • Auburn, California + 438 more

Conditions: Anxiety Disorders, Public Speaking Fear
Interventions: Exposure, Rehearsal; Behavioral
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years and older
Enrollment: 88 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Breast Cancer, Breast Neoplasms, Breast Diseases
Interventions: Biospecimen Collection, Surgical Tissue Collection, Survey Collection; Other · Diagnostic Test · Behavioral
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 800 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2030
U.S. locations: 3
States / cities: Los Angeles, California • Miami, Florida • New York, New York

Conditions: Intracranial Meningioma, Recurrent Meningioma, NF2 Gene Mutation
Interventions: Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, Abemaciclib; Drug
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older
Enrollment: 124 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2029
U.S. locations: 791
States / cities: Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 512 more

Search by objective public record fields.

Glucosamine/Chondroitin Arthritis Intervention Trial (GAIT)

A Study of 177Lu-FAP-2286 in Advanced Solid Tumors

Improving Attention Skills of Children With Autism

Mycobacteriophage Treatment of Non-tuberculosis Mycobacteria

Comparison of Trimetrexate Plus Leucovorin Calcium Rescue Versus Sulfamethoxazole-Trimethoprim in the Treatment of Pneumocystis Carinii Pneumonia (PCP) in Patients With AIDS

A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations

HCRN Core Data Project: Characterizing Patient Populations in the Hydrocephalus Clinical Research Network (HCRN)

Menopausal HT for Women Living With HIV (HoT)

Testing the Use of the Immunotherapy Drugs Ipilimumab and Nivolumab Plus Radiation Therapy Compared to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Unmethylated Glioblastoma

An Efficacy and Safety Study of SRM003 in the Treatment of Subjects Undergoing Placement of an Arteriovenous Graft to Facilitate Hemodialysis Access

A Study to Evaluate the Efficacy and Safety of Rituximab Versus Mycophenolate Mofetil (MMF) in Participants With Pemphigus Vulgaris (PV)

Study of the Effects of Pre-surgical Aerobic Exercise on Patients With Solid Tumors

Phase 3 Trial in Subjects With Metastatic Melanoma Comparing 3 mg/kg Ipilimumab Versus 10 mg/kg Ipilimumab

Efficacy and Safety of Ofatumumab and Siponimod Compared to Fingolimod in Pediatric Patients With Multiple Sclerosis

An Evaluation of Epic EHR AI Outpatient Chart Summarization

Validation of RPVi as a Parameter to Predict Fluid Responsiveness

Omegaven Treatment of Parenteral Nutrition (PN) Induced Liver Injury

A Phase I Study of Safety and Pharmacokinetics of Nevirapine in HIV-1 Infected Pregnant Women and Neonates Born to HIV-1 Infected Mothers

Dendritic Cell Vaccine for Patients With Brain Tumors

Sorafenib and Topotecan in Refractory/Recurrent Pediatric Malignancies

Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed by the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed by Surgery

Reward Processes and Rehearsal in Exposure Therapy

A Study of Breast Cancer Risk Factors and Outcomes of People in Florida

Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas